Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have received at least one dose of dabrafenib or combination with trametinib as part of a compassionate use for the treatment of metastatic melanoma, with deadline the start of treatment the April 30, 2014.~Exclusion Criteria:~* Patients with a history not available.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabrafenib (Type: None): None
- Dabrafenib plus Trametinib (Type: None): Patients treated with Dabrafenib plus Trametinib

Based on this trial design, predict the completion outcome and termination type (if applicable).